Alex Azar II, Son of Ophthalmologist, is New Secretary of Health and Human Services

February 2, 2018: By Joan McKenna

Alex Azar II

Alex Azar II, the son of ophthalmologist Alex Azar, MD, is the new secretary of the US Department of Health and Human Services.

The Senate confirmed Azar’s nomination Jan. 24.

The senior Azar has practiced ophthalmology in Salisbury, Maryland, since 1976 and teaches at Johns Hopkins. He told a local paper that his son’s appointment is the epitome of the American dream, given that his father immigrated to the US from Lebanon 100 years ago.

The new secretary, 50, worked at Lilly USA from 2007 to January 2017, ascending to the role of president. He served as general counsel and deputy secretary in Health and Human Services in the George W. Bush administration.

He earned a law degree from Yale, then clerked for Judge Antonin Scalia in an appeals court. He also worked under special prosecutor Ken Starr in the early years of the Whitewater investigation.

Sen. Rand Paul, MD, an ophthalmologist from Kentucky, was the only GOP member to vote against Azar’s nomination. Paul said he couldn’t back confirmation unless Azar showed he was open to the idea of allowing drugs to be imported from other countries where they often cost much less.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023